Effects of Delta-9-THC and Iomazenil in Healthy Humans


Mental Disorders | Psychotic Disorders | Schizophrenia

Trial Phase

Phase 1

Trial Purpose and Description

Trial Purpose

The study aims to examine the combined effects of delta-9-tetrahydrocannabinol (∆-9-THC or THC) and iomazenil on thinking, perception, mood, memory, attention, and electrical activity of the brain (EEG). THC is the active ingredient of marijuana, cannabis, "ganja", or "pot". Iomazenil is a drug that works opposite to drugs like valium. The purpose of this study is to determine whether the administration of iomazenil will alter the effects of THC.

Participation Guidelines

18 Years - 55 Years

Eligibility Criteria

Inclusion Criteria:

- Exposed to cannabis at least once in their lifetime

Exclusion Criteria:

- Cannabis naïve

- History of hearing deficit
Yale University
February 2009
Last Updated:
June 13, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT00982982